Musunuru provided ESGCT delegates with promising news of a roadmap following the diagnosis and treatment of Baby KJ.
In April 2025, AstraZeneca announced that its experimental oral PCSK9 inhibitor, AZD0780, achieved a 50.7% reduction in LDL ...
CRISPR therapies offer precise gene-editing solutions for treating genetic disorders and other complex diseases. Rising prevalence of genetic conditions drives adoption, and emerging CRISPR-based ...
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common ...
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with ...
Zacks Investment Research on MSN
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
Delve into Eli Lilly’s biopharma strategy as it advances its pipeline, wins regulatory milestones, and forges strategic deals ...
Wonderful. Thank you, guys. It is wonderful to see you all here today. Thank you so much for taking the time. It is my privilege to have the Viking team here with me. I've got Gregory and Brian, CEO ...
Minneapolis hosts the final Open Streets 2025 event on Hennepin Avenue, turning it into a car-free zone for community engagement.
Thanks to a partnership with Ionis Pharmaceuticals, Biogen has a long history with antisense oligonucleotides, which can modify the production of proteins in the body. The two companies developed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback